At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Bromhexine Hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·interventional·Posted May 28, 2020·Updated Apr 13, 2022
In Brief
A Phase 4 clinical trial evaluating Bromhexine Hydrochloride for Increased Risk of SARS-CoV-2 Infection. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This is a randomized controlled trial of the efficacy and safety evaluation of oral administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting patients with a new coronavirus disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIncreased Risk of SARS-CoV-2 Infection
CountriesRussia
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedMay 2020
Primary CompletionAug 2020
Study CompletionAug 2020
TodayJul 2026
First PostedMay 28, 2020
Enrollment StartMay 14, 2020
Primary CompletionAug 9, 2020
Study CompletionAug 31, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.1 years ago
Interventions
Bromhexine Hydrochloridedrug
Medical personnel at risk for COVID-19 infection will receive study medication for 14 days